• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

4.070 +0.040 (+0.99%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 588,947
Open 4.100
Bid (Size) 4.000 (400)
Ask (Size) 4.120 (1,000)
Prev. Close 4.030
Today's Range 4.020 - 4.145
52wk Range 3.860 - 8.480
Shares Outstanding 25,938,064
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 02, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
September 28, 2026
From Immuneering Corporation
Via GlobeNewswire

Performance

52-Week Range 52.0% below 52-week high
4.070
3.8652W Low 8.4852W High
1 Week 4.2% below 1-week high
4.011W Low 4.251W High

Immuneering Corporation - Class A Common Stock (IMRX) traded between $3.86 and $8.48 over the past 52 weeks and last traded at $4.07, 52.0% below its 52-week high. Over the past week it ranged between $4.01 and $4.25.

Past 12 Months
-2.2%
-15.6%
-20.8%
-24.6%
-38.5%
-35.2%
1W -$0.09
1M -$0.75
3M -$1.07
6M -$1.33
YTD -$2.55
1Y -$2.21

IMRX was -35.2% over the past year, -24.6% over six months, -38.5% year to date, -2.2% in the last week.

12 Months vs Market
IMRX
-35.2%
DIA
+9.5%
SPY
+14.6%
QQQ
+23.3%
IWM
+14.1%

Over the past 12 months IMRX returned -35.2% versus DIA (Dow) +9.5%, SPY (S&P 500) +14.6%, QQQ (Nasdaq 100) +23.3% and IWM (Russell 2000) +14.1%.

Volume & Liquidity 0.82× 3-mo avg
Today 588,947 3-mo avg 714.9K
1W
579.4K
1M
716.5K
3M
714.9K
6M
1.1M
YTD
1.3M
1Y
1.3M

IMRX most recently traded 588,947 shares against a 3-month average daily volume of 714.9K.

More News

Read More
News headline image
Immuneering to Present at the ESMO Congress 2026
September 24, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
September 10, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Participate in Upcoming Investor Conferences
September 03, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
August 26, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 05, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
July 21, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Corporation Announces Grants of Inducement Awards
July 17, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Appoints Andrew Gengos as Chief Financial Officer
June 15, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
June 11, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
June 01, 2026
From Immuneering Corporation
Via GlobeNewswire
Friday's session: gap up and gap down stocks ↗
May 22, 2026
Via Chartmill
News headline image
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
May 21, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
May 15, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
April 21, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
April 20, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
April 06, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
March 17, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 06, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the Leerink Global Healthcare Conference
March 02, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 18, 2026
From Immuneering Corporation
Via GlobeNewswire
Here are the top movers in Thursday's session. ↗
January 08, 2026
Via Chartmill
These stocks are gapping in today's session ↗
January 08, 2026
Via Chartmill
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
January 08, 2026
Via Chartmill

Frequently Asked Questions

Is Immuneering Corporation - Class A Common Stock publicly traded?
Yes, Immuneering Corporation - Class A Common Stock is publicly traded.
What exchange does Immuneering Corporation - Class A Common Stock trade on?
Immuneering Corporation - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immuneering Corporation - Class A Common Stock?
The ticker symbol for Immuneering Corporation - Class A Common Stock is IMRX on the Nasdaq Stock Market
What is the current price of Immuneering Corporation - Class A Common Stock?
The current price of Immuneering Corporation - Class A Common Stock is 4.070
When was Immuneering Corporation - Class A Common Stock last traded?
The last trade of Immuneering Corporation - Class A Common Stock was at 10/02/26 04:00 PM ET
What is the market capitalization of Immuneering Corporation - Class A Common Stock?
The market capitalization of Immuneering Corporation - Class A Common Stock is 105.57M
How many shares of Immuneering Corporation - Class A Common Stock are outstanding?
Immuneering Corporation - Class A Common Stock has 106M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap